However, sorafenib was shown to bemore effective in leukemia with the FLT3-ITD mutation,and its antileukemic function was clarified in severalpatients with AML and wild-type form of FLT3 (31).In our previous study, we demonstrated that sorafenibdownregulates the gene expression of VEGFR-1/2 inKG-1 cell line and downregulates the gene expression ofVEGF-A in U937 cell line (32). This evidence concerns the gene FLT3 and acute myeloid leukemia.